Sugammadex Piramal



This medicine is authorised for use in the European Union.


Sugammadex Piramal is a medicine used to reverse the effect of the muscle relaxants rocuronium and vecuronium. Muscle relaxants are medicines used during some types of operation to make the muscles relax, including the muscles that help the patient to breathe. Muscle relaxants make it easier for the surgeon to do the operation. Sugammadex Piramal is used to speed up the recovery from the muscle relaxant, usually at the end of the operation.

Sugammadex Piramal can be used in adults who have received rocuronium and vecuronium, and in children aged 2 years or older who have received rocuronium.

Sugammadex Piramal is a ‘generic medicine’. This means that Sugammadex Piramal contains the same active substance and works in the same way as a ‘reference medicine’ already authorised in the EU. The reference medicine for Sugammadex Piramal is Bridion.

Sugammadex Piramal contains the active substance sugammadex.

This EPAR was last updated on 18/07/2023

Authorisation details

Product details
Sugammadex Piramal
Agency product number
Active substance
sugammadex sodium
International non-proprietary name (INN) or common name
Therapeutic area (MeSH)
Neuromuscular Blockade
Anatomical therapeutic chemical (ATC) code

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see Generic and hybrid medicines.

Publication details
Marketing-authorisation holder
Piramal Critical Care B.V.
Date of issue of marketing authorisation valid throughout the European Union
Contact address

Rouboslaan 32
2252 TR Voorschoten

Product information

23/06/2023 Sugammadex Piramal - EMEA/H/C/006083 -

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.


Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group


Therapeutic indication

Reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults.

Assessment history

How useful was this page?

Add your rating